TC-1698

TC-1698
(IUPAC) ime
	2-piridin-3-il-1-azabiciklo[3.2.2]nonan
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	10130417
Hemijski podaci
Formula	C13H18N2
Mol. masa	202,295
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C13H18N2/c1-2-12(10-14-7-1)13-4-3-11-5-8-15(13)9-6-11/h1-2,7,10-11,13H,3-6,8-9H2 ; Key: WIEWCOLOPGXZDJ-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Legal

TC-1698 je lek koji deluje kao parcijalni agonist na α7 tipu neuronskog nikotinskog acetilholinskog receptora.^[3] On ima neuroprotektivne efekte u žibotinjskim studijama,^[4] i korišten je kao vodeće jedinjenje za razvoj potentnih derivata.^[5]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). „Central nicotinic receptors: structure, function, ligands, and therapeutic potential”. ChemMedChem 2 (6): 746–767. DOI:10.1002/cmdc.200600207. PMID 17295372.
↑ Marrero, M.; Papke, R.; Bhatti, B.; Shaw, S.; Bencherif, M. (2004). „The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo3.2.2nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase”. The Journal of Pharmacology and Experimental Therapeutics 309 (1): 16–27. DOI:10.1124/jpet.103.061655. PMID 14722323.
↑ Bhatti, B.; Strachan, J.; Breining, S.; Miller, C.; Tahiri, P.; Crooks, P.; Deo, N.; Day, C. i dr.. (2008). „Synthesis of 2-(pyridin-3-yl)-1-azabicyclo3.2.2nonane, 2-(pyridin-3-yl)-1-azabicyclo2.2.2octane, and 2-(pyridin-3-yl)-1-azabicyclo3.2.1octane, a class of potent nicotinic acetylcholine receptor-ligands”. The Journal of Organic Chemistry 73 (9): 3497–3507. DOI:10.1021/jo800028q. PMID 18363376.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). „Central nicotinic receptors: structure, function, ligands, and therapeutic potential”. ChemMedChem 2 (6): 746–767. DOI:10.1002/cmdc.200600207. PMID 17295372.

[4] Marrero, M.; Papke, R.; Bhatti, B.; Shaw, S.; Bencherif, M. (2004). „The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo3.2.2nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase”. The Journal of Pharmacology and Experimental Therapeutics 309 (1): 16–27. DOI:10.1124/jpet.103.061655. PMID 14722323.

[5] Bhatti, B.; Strachan, J.; Breining, S.; Miller, C.; Tahiri, P.; Crooks, P.; Deo, N.; Day, C. i dr.. (2008). „Synthesis of 2-(pyridin-3-yl)-1-azabicyclo3.2.2nonane, 2-(pyridin-3-yl)-1-azabicyclo2.2.2octane, and 2-(pyridin-3-yl)-1-azabicyclo3.2.1octane, a class of potent nicotinic acetylcholine receptor-ligands”. The Journal of Organic Chemistry 73 (9): 3497–3507. DOI:10.1021/jo800028q. PMID 18363376.

[3]

[4]

[5]

[1]

[2]